See more : PT Tempo Inti Media Tbk (TMPO.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Axcella Health Inc. (AXLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axcella Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Concrete Pumping Holdings, Inc. WT EXP 080124 (BBCPW) Income Statement Analysis – Financial Results
- Witted Megacorp Oyj (WITTED.HE) Income Statement Analysis – Financial Results
- Yarn Syndicate Limited (YARNSYN.BO) Income Statement Analysis – Financial Results
- Yangarra Resources Ltd. (YGR.TO) Income Statement Analysis – Financial Results
- Indus Towers Limited (INDUSTOWER.BO) Income Statement Analysis – Financial Results
Axcella Health Inc. (AXLA)
About Axcella Health Inc.
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.98M | 43.14M | 37.04M | 41.66M | 25.49M | 22.92M |
| General & Administrative | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.82M | 18.71M | 16.80M | 15.78M | 8.41M | 6.01M |
| Other Expenses | 0.00 | -4.00K | 10.00K | 34.00K | 0.00 | 0.00 |
| Operating Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Cost & Expenses | 72.80M | 61.85M | 53.84M | 57.44M | 33.90M | 28.92M |
| Interest Income | 504.00K | 139.00K | 306.00K | 1.81M | 0.00 | 0.00 |
| Interest Expense | 3.02M | 2.92M | 3.01M | 3.40M | 0.00 | 0.00 |
| Depreciation & Amortization | 412.00K | 288.00K | 419.00K | 51.00K | 1.07M | 1.39M |
| EBITDA | -67.01M | -61.85M | -53.84M | -57.39M | -32.81M | -27.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.80M | -61.85M | -53.84M | -57.44M | -33.90M | -28.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.39M | -2.78M | -2.69M | -1.60M | -2.17M | -2.02M |
| Income Before Tax | -81.19M | -64.63M | -56.53M | -59.04M | -36.07M | -30.94M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.49M | 2.28M | 936.00K | -2.17M | 2.02M |
| Net Income | -81.19M | -67.12M | -58.81M | -59.97M | -36.07M | -30.94M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| EPS Diluted | -1.49 | -1.76 | -1.85 | -3.61 | -2.18 | -1.87 |
| Weighted Avg Shares Out | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
| Weighted Avg Shares Out (Dil) | 54.36M | 38.11M | 31.75M | 16.62M | 16.53M | 16.53M |
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today outlined key clinical and operational milestones that are expected for the company in...
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today outlined key clinical and operational milestones that are expected for the company in 2022....
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the...
Down 24% in 4 Weeks, Here's Why Axcella Health Inc. (AXLA) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Axcella Health Inc. (AXLA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, and researchers at the Oxford University Radcliffe Department of Medicine today announced that patient screening...
Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, and researchers at the Oxford University Radcliffe Department of Medicine today announced that patient...
Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Axcella Health Inc. (AXLA)
Axcella Health Inc. (AXLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been promoted to the role of Chief...
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical...
Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will be participating in the Piper Sandler 33rd Annual Healthcare Conference....
Source: https://incomestatements.info
Category: Stock Reports